| scholarly article | Q13442814 |
| P50 | author | Stephanie Daignault | Q110591794 |
| P2093 | author name string | James E Montie | |
| Rodney L Dunn | |||
| David P Wood | |||
| Cheryl T Lee | |||
| Yingxi Zhang | |||
| Rabii Madii | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bladder cancer | Q504775 |
| cancer diagnosis | Q110324059 | ||
| P304 | page(s) | 1262-7; discussion 1267 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Journal of Urology | Q15709979 |
| P1476 | title | Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival | |
| P478 | volume | 175 |
| Q58691149 | A Festschrift in Honor of Edward M. Messing, MD, FACS |
| Q90225546 | A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging |
| Q79508629 | A rationale for developing benchmarks for the treatment of muscle-invasive bladder cancer |
| Q36710334 | An analysis of preoperative delays prior to radical cystectomy for bladder cancer in Quebec |
| Q92671480 | Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer |
| Q46162263 | Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. |
| Q35576964 | Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer |
| Q90609309 | Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years |
| Q57166936 | Circulating Tumour DNA in Muscle-Invasive Bladder Cancer |
| Q84173659 | Clinical trials: nationally representative data in urology |
| Q37953115 | Comprehensive handbook for developing a bladder cancer cystectomy database |
| Q37037452 | Considerations on the use of diagnostic markers in management of patients with bladder cancer. |
| Q36389716 | Contemporary management of muscle-invasive bladder cancer |
| Q39177293 | Contemporary update on neoadjuvant therapy for bladder cancer |
| Q37261942 | Current status of prostate-sparing cystectomy |
| Q38261490 | Delay in diagnosis of cancer as a patient safety issue - a root cause analysis based on a representative case report |
| Q37016321 | Delay of cystectomy: for whom does it really matter? |
| Q84603668 | Delays in diagnosis and bladder cancer mortality |
| Q38018207 | Diagnosis and treatment of bladder cancer: how can we improve? |
| Q98386718 | Diagnostic and treatment delays among patients with primary bladder cancer in Poland: a survey study |
| Q87232931 | Disparity in bladder cancer outcomes: what's sex got to do with it? |
| Q90041001 | Downstream Studies Following the Use of Bone Scan in the Staging of Muscle-invasive Bladder Cancer |
| Q95584507 | EDITORIAL COMMENT |
| Q41923384 | ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy |
| Q84153499 | Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach |
| Q84604690 | Examining the association between delay in diagnosis and decreased survival in bladder cancer |
| Q38770375 | Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer |
| Q47259653 | Gender-dependent cancer-specific survival following radical cystectomy |
| Q97088002 | Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic |
| Q90293717 | Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy |
| Q53130636 | Impact of resident involvement in endoscopic bladder cancer surgery on pathological outcomes. |
| Q38086051 | Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival |
| Q36606956 | Improving outcomes with radical cystectomy for high-grade invasive bladder cancer |
| Q36990725 | Improving the prognosis of patients after radical cystectomy. Part II: the role of perioperative chemotherapy |
| Q46033293 | Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma. |
| Q36749513 | Lunar phases and zodiac signs do not influence quality of radical cystectomy--a statistical analysis of 452 patients with invasive bladder cancer |
| Q37523855 | Management of bladder cancer: current and emerging strategies |
| Q26775772 | Management of carcinoma in situ of the bladder: best practice and recent developments |
| Q37260277 | Management of muscle-invasive bladder cancer: an update |
| Q37125906 | Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. |
| Q37955283 | Neoadjuvant and adjuvant chemotherapy for locally advanced bladder carcinoma: development of novel bladder preservation approach, Osaka Medical College regimen |
| Q37375315 | Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings |
| Q79370791 | Neoadjuvant chemotherapy for bladder cancer |
| Q33758673 | Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions |
| Q37508037 | Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer |
| Q82292813 | Nucleotide Excision Repair Gene Polymorphisms May Predict Acute Toxicity in Patients Treated with Chemoradiotherapy for Bladder Cancer |
| Q55222705 | Oncological Outcome of Primary and Secondary Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis. |
| Q80792635 | Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy |
| Q88886395 | Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma |
| Q38592301 | Patient Psoas Muscle Mass as a Predictor of Complications and Survival After Radical Cystectomy |
| Q51694266 | Patterns of hematuria referral to urologists: does a gender disparity exist? |
| Q41729156 | Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy. |
| Q37472550 | Perioperative chemotherapy for muscle-invasive bladder cancer. |
| Q41264196 | Perioperative chemotherapy: the case for adjuvant chemotherapy for muscle-invasive bladder cancer |
| Q37103989 | Predicting survival after radical cystectomy for bladder cancer |
| Q36502817 | Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients |
| Q33762096 | Prognostic role of matrix metalloproteinases in bladder carcinoma: a systematic review and meta-analysis |
| Q36879159 | Prostate-sparing cystectomy: has Pandora's box been opened? |
| Q50851269 | Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study. |
| Q47567960 | Reducing Overutilization of Preoperative Medical Referrals among Patients Undergoing Radical Cystectomy Using an Evidence-Based Algorithm |
| Q35125750 | Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder |
| Q37564393 | Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. |
| Q38610919 | Surgical and pathological outcomes of robotic-assisted radical cystectomy for bladder cancer in the community setting |
| Q38710592 | Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment |
| Q39513953 | The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer |
| Q36805552 | The effect of delaying nephrectomy on oncologic outcomes in patients with renal tumors greater than 4cm. |
| Q40170786 | The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis |
| Q60054615 | The impact of patient-related nonmodifiable factors on perioperative outcomes following radical cystectomy with enhanced recovery protocol |
| Q35028256 | The time from diagnosis of bladder cancer to radical cystectomy in Polish urological centres - results of CysTiming Poland study |
| Q35533822 | Timing of radical cystectomy in Central Europe - multicenter study on factors influencing the time from diagnosis to radical treatment of bladder cancer patients |
| Q91933789 | Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer |
| Q92165123 | Treatment delays for muscle-invasive bladder cancer |
| Q44761739 | Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study |
| Q53159064 | Trends in the use of radiotherapy and radical surgery for patients with bladder urothelial cell carcinoma in East Anglia, 1995-2006. |
| Q37371831 | Understanding bladder cancer death: tumor biology versus physician practice |
| Q36171243 | Update on the management of invasive bladder cancer 2012. |
| Q34553950 | Upper tract urothelial carcinoma: Impact of time to surgery |
| Q40459374 | Urinary tract infection-like symptom is associated with worse bladder cancer outcomes in the Medicare population: Implications for sex disparities. |
| Q36640991 | Use of nomograms as predictive tools in bladder cancer. |
| Q47592266 | Utilization of perioperative systemic chemotherapy in upper tract urothelial carcinoma. |
| Q43202165 | Wait times from diagnosis to treatment in cancer |
| Q81099394 | [Is there an indication for adjuvant or neoadjuvant systemic chemotherapy in bladder cancer?] |
| Q80494727 | [The latest news on bladder cancer] |
Search more.